AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KSEP 171 min read$ORMP

ORAMED PHARMACEUTICALS INC. (ORMP): Submission of Matters to a Vote of Security Holders

ORAMED PHARMACEUTICALS INC. (ORMP) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On September 15, 2026, the Company held its 2026 Annual Meeting of Stockholders. The final voting results at the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) are set forth below. Proposal No. 1 - Re-ele

Original reporting
SEC EDGAR 8-K
Published Sep 17, 2026, 7:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 7:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$ORMP
Neutral
high confidence
Mentioned
$ORMP
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ORMPNeutralLow
01

Why it matters

The filing confirms routine governance actions with no material operational or financial changes.

02

Market read

A standard corporate‑governance disclosure; limited relevance for traders.

03

What to watch

Potential future compensation alignment changes from the new say‑on‑pay frequency.

Relevance 6/10Novelty 3/10Timing: filed Sep 17, 2026, two days after the annual meeting

Background

ORMP held its 2026 Annual Meeting on Sep 15, 2026, and filed the results via an SEC Form 8‑K two days later.

Company-level read

Ticker impact

$ORMPNeutralHigh confidence
Context

SEC Form 8‑K discloses the results of ORMP's 2026 Annual Meeting, including director re‑elections and shareholder approvals of say‑on‑pay and stock‑plan amendments.

Expected impact

minimal; price likely unchanged

Evidence & confidence

The filing reports standard voting results; no material change to capital structure or strategy.

Market effects

Sector

none; governance update does not affect the broader pharmaceutical sector.

Regional

none; filing pertains only to ORMP shareholders.

Global

none

Counterpoint

What could challenge this read

Investors could view the expanded stock‑incentive plan as a slight dilution risk, but the impact is negligible.

Key entities

  • company
    ORAMED PHARMACEUTICALS INC.

    Subject of the filing; a pharmaceutical company listed on US exchanges.

Read at source← All news

Related articles

AUG 28
$NEOHighAI 8/10

Biotech Stocks At 52-Week Highs - NEO, BLSM, RVMD, ORMP, CADL

NeoGenomics (NEO), BlossomHill Therapeutics (BLSM), Revolution Medicines (RVMD), Oramed Pharmaceuticals (ORMP), and Candel Therapeutics (CADL) reached 52-week highs on August 27, 2026. NEO reported Q2 revenue growth of 11% and a profit turnaround. BLSM began trading on Nasdaq and received FDA Fast Track designation. RVMD's lead drug, Rasonque, was FDA-approved. ORMP's net income increased significantly. CADL reported a higher net loss but plans a BLA filing for its lead drug.

rttnews.com4 min
OCT 19
$EQTLow

EQT’s Dividend Faces a Big Test: Can Natural Gas Cash Flow Hold Up?

EQT (NYSE:EQT) raised its quarterly dividend to $0.17 per share, up 3% from $0.165. The company generated $2.50B in free cash flow in 2025, covering dividends 6.4 times. Despite a 29.2% revenue drop in Q2 2026, free cash flow still covered dividends 4.4 times. EQT aims to reduce debt to $5B and prioritize buybacks over dividend growth.

247wallst.com2 min
OCT 19
$MSTRMed

Strategy's Third Purchase This Month Brings Spending To $73M

Strategy, the largest corporate holder of bitcoin, acquired 267 BTC for $22M, increasing its holdings to 848,517 BTC. This brings its October spending to $73M. MSTR stock rose 2% to $139, despite a 17% drop over the past month. The company also repurchased $193.1M of its preferred stock. Strategy's bitcoin investments total $64B, and it offers preferred shares for yield. MSCI's proposal to exclude non-operating companies may impact its index inclusion.

bitcoinmagazine.com2 min
OCT 19
Low

Modal Adopts Nvidia Vera Chip for AI Agent Workloads

Modal, a New York-based AI computing startup, is adding Nvidia's Vera CPU to its server lineup, citing doubled AI agent performance. The company's valuation reached $15.75 billion, with $1 billion in projected sales. Modal uses a multi-cloud model and partners with companies like DoorDash and Runway. Nvidia expects $20 billion in Vera chip sales this fiscal year, competing with Intel and AMD.

hoodline.com2 min
OCT 19
$NMRKMedAI 8/10

Newmark arranges $369M Fannie Mae facility for Florida housing

Newmark Group (NASDAQ:NMRK) arranged a $369M Fannie Mae credit facility for April Housing, supporting an 11-property affordable housing portfolio in Florida. The financing includes a $221.4M fixed-rate draw and a $147.6M floating-rate draw. Newmark's team led the transaction, which involved complex regulatory agreements. April Housing aims to preserve affordability in the communities. Newmark reported $3.6B in revenues for the year ended June 30, 2026.

investing.com2 min